

Short- and long-read transcriptomics in FTLD-TDP identifies unique disease-associated transcripts generated by aberrant splicing

Júlia Faura, Cyril Pottier, Matthew C. Baker, Mariely DeJesus-Hernandez, Sarah Wynants, Marleen Van den Broeck, Tim De Pooter, Geert Joris, NiCole Finch, Marka Van Blitterswijk, Joanna Biernacka, Yan Asmann, Mojca Strazisar, Melissa E. Murray, Leonard Petrucelli, Bjorn Okarsson, Keith A. Josephs, Ronald C. Petersen, Bradley F. Boeve, Neill R. Graff-Radford, Dennis W. Dickson, Rosa Rademakers

State of the art: Dysregulation of TDP-43 as seen in TDP-43 proteinopathies leads to specific RNA splicing dysfunction. While short-read RNA-sequencing (RNA-seq) has been widely used for transcriptomics profiling, long-read transcriptome sequencing is emerging as a powerful alternative. We hypothesize that short- and long-read transcriptomics data of FTLD-TDP brains can highlight novel disease-associated transcripts with relevance to the identification of disease pathways and biomarkers.

Methodology: We performed the largest differential splicing and differential transcript usage (DTU) analyses to date in FTLD-TDP patients using short-read RNA-seq data from frontal-cortex (FCX) tissue of 127 patients and 22 control subjects (Mayo Clinic Brain Bank; HiSeq4000, Illumina), using LeafCutter, Kallisto and DRIMSeq. In addition, long-read direct cDNA sequencing of FCX brain tissue was optimized on the Oxford Nanopore Technology PromethION platform.

Results: We identified 2667 differentially spliced events between FTLD-TDP and control subjects in 812 unique genes ($FDR < 0.05$, $|dPSI| > 0.1$). Fifty-eight of these were cryptic events (29 unique genes) and more frequent in FTLD-TDP cases compared to controls. Four of these, *STMN2* and three novel genes implicated in modulating GTPase activity, overlapped with cryptic events previously reported upon TDP-43 knock-down in human neurons suggesting a direct link to TDP-43 dysfunction. Long-read sequencing of cDNA derived from FCX is ongoing to complement the short-read data and validate novel TDP-43 targets.

Conclusion: Using the largest short-read FTLD-TDP transcriptome dataset available to date, we validated *STMN2* and identified disease-associated transcripts. The long-read data will be used to validate our findings and identify more aberrant splicing events in FTLD-TDP.

Conflicts of interest

N/A